Skip to content

A randomized double-blind parallel controlled clinical study on the improvement of skin lesions in patients with mild to moderate atopic dermatitis using traditional Chinese medicine bath lotion "Mu Sheng Shu"

A randomized double-blind parallel controlled clinical study on the improvement of skin lesions in patients with mild to moderate atopic dermatitis using traditional Chinese medicine bath lotion "Mu Sheng Shu"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001206
Enrollment
Unknown
Registered
2025-06-18
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Experimental Group:Langyoutang Traditional Chinese Medicine Bath Milk "Mu Sheng Shu"
Control group:Placebo

Sponsors

Shanghai Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: a. Meets the Williams diagnostic criteria for atopic dermatitis; b. Gender is not limited age range is 18-50 years old; c. The target skin lesion has a diameter of 2-10 cm and is located in the limbs or trunk; d. Mild to moderate atopic dermatitis with an eczema area and severity index (EASI) score of = 21; e. The area of skin lesions before treatment is less than 10% of the body surface area (evaluated by the palm method with the patient's palm area defined as 1%); f. Sign the informed consent form voluntarily participate in this project and adhere to regular follow-up as required.

Exclusion criteria

Exclusion criteria: a. Pregnant or lactating women; b. Received AD system treatment within three months, and received local treatment or phototherapy within the past two weeks; c. Having serious systemic diseases such as heart, lung, gastrointestinal, liver, kidney, or mental illnesses; d. Suffering from systemic diseases or active skin diseases (such as psoriasis) that may affect the evaluation of test results; e. Patients with scars, birthmarks, tattoos, sunspots, etc. on the affected area that may affect the evaluation of skin lesions; f. Patients with concurrent bacterial, viral, and fungal infections in the affected area who require anti infective treatment; g. Patients who have participated or are currently participating in clinical trials of other experimental products within one month; h. Individuals with communication barriers who are unable to independently complete the questionnaire survey.

Design outcomes

Primary

MeasureTime frame
EASI50;

Secondary

MeasureTime frame
Recurrence rate;visual analogue scale;investigator's global assessment;dermatology life quality index;

Countries

China

Contacts

Public ContactRuiping Wang

Shanghai Skin Disease Hospital

w19830901@126.com13816845803

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 23, 2026